Climb Bio CLYM
$9.19 −$0.09 (-0.97%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $9.03 -1.76%
Open$8.98
Prev close$9.28
Day range$8.90 – $9.40
Volume770.2K
Market cap$539.80M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$16.89M-13.4% YoY
Net profit-$14.57M-13.1% YoY
Diluted EPS-$0.18+5.3% YoY
Free cash flow-$12.82M-4.7% YoY
Operating cash flow-$12.00M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-29.3%
Return on assets-28.3%
Return on invested capital-32.9%
Current ratio26.58
Liabilities / assets3.6%
Cash & investments$205.42M
Total debt$605,000.00
Net cash (debt)$204.82M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $16.89M | $15.36M | $15.21M | $67.88M | $19.30M |
| Selling and Admin Expenses | $5.85M | $5.65M | $5.84M | $21.17M | $5.56M |
| -General & Admin Expense | $5.85M | $5.65M | $5.84M | $21.17M | $5.56M |
| Research & Development | $11.04M | $9.71M | $9.37M | $46.71M | $13.74M |
| Operating Profit | -$16.89M | -$15.36M | -$15.21M | -$67.88M | -$19.30M |
| Net Non-Operating Interest Income (Expense) | $2.33M | $1.86M | $1.51M | $8.32M | $1.83M |
| Non-Operating Interest Income | $2.33M | $1.86M | $1.51M | $8.32M | $1.83M |
| Other Income (Expense) | -$5,000.00 | $6,000.00 | -$25,000.00 | -$291,000.00 | -$46,000.00 |
| Gain on Sale of Security | -$5,000.00 | $6,000.00 | -$25,000.00 | -$291,000.00 | -$46,000.00 |
| Pretax Profit | -$14.57M | -$13.50M | -$13.72M | -$59.85M | -$17.52M |
| Net Profit | -$14.57M | -$13.50M | -$13.72M | -$59.85M | -$17.52M |
| Profit from Continuing Operations | -$14.57M | -$13.50M | -$13.72M | -$59.85M | -$17.52M |
| Net Income to Parent Company | -$14.57M | -$13.50M | -$13.72M | -$59.85M | -$17.52M |
| Net Income to Common Stockholders | -$14.57M | -$13.50M | -$13.72M | -$59.85M | -$17.52M |
| Basic EPS | -$0.18 | -$0.18 | -$0.20 | -$0.88 | -$0.26 |
| Diluted EPS | -$0.18 | -$0.18 | -$0.20 | -$0.88 | -$0.26 |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $236.56M | $246.29M | $152.37M | $167.74M | $167.74M |
| Total Current Assets | $210.15M | $186.64M | $113.40M | $105.85M | $105.85M |
| Cash and Cash Equivalents & Short-Term Investments | $205.42M | $183.12M | $109.56M | $101.08M | $101.08M |
| -Cash and Cash Equivalents | $39.73M | $44.11M | $8.36M | $35.69M | $35.69M |
| -Short Term Investments | $165.69M | $139.02M | $101.21M | $65.40M | $65.40M |
| Other Current Assets | $4.73M | $3.51M | $3.84M | $4.77M | $4.77M |
| Total Non-Current Assets | $26.42M | $59.66M | $38.97M | $61.90M | $61.90M |
| Net PPE | $2.32M | $1.91M | $697,000.00 | $793,000.00 | $793,000.00 |
| -Gross PPE | $2.32M | $1.91M | $697,000.00 | $793,000.00 | $793,000.00 |
| Investments and Advances | $22.20M | $56.10M | $36.74M | $59.57M | $59.57M |
| -Available for Sale Securities | $22.20M | $56.10M | $36.74M | $59.57M | $59.57M |
| Other Non-Current Assets | $1.89M | $1.65M | $1.53M | $1.53M | $1.53M |
| Total Liabilities | $8.51M | $6.75M | $4.29M | $7.27M | $7.27M |
| Total Current Liabilities | $7.91M | $5.93M | $4.07M | $6.98M | $6.98M |
| Payables | $1.06M | $1.13M | $860,000.00 | $2.27M | $2.27M |
| -Accounts Payable | $1.06M | $1.13M | $860,000.00 | $2.27M | $2.27M |
| Current Accrued Expenses | $6.39M | $4.30M | $2.95M | $4.46M | $4.46M |
| Short-Term Debt and Capital Lease Obligation | $463,000.00 | $501,000.00 | $263,000.00 | $256,000.00 | $256,000.00 |
| -Current Capital Lease Obligation | $463,000.00 | $501,000.00 | $263,000.00 | $256,000.00 | $256,000.00 |
| Total Non-Current Liabilities | $605,000.00 | $813,000.00 | $216,000.00 | $285,000.00 | $285,000.00 |
| Long Term Debt and Capital Lease Obligation | $605,000.00 | $813,000.00 | $216,000.00 | $285,000.00 | $285,000.00 |
| -Long Term Capital Lease Obligation | $605,000.00 | $813,000.00 | $216,000.00 | $285,000.00 | $285,000.00 |
| Total Equity | $228.05M | $239.55M | $148.09M | $160.48M | $160.48M |
| Stockholders' Equity | $228.05M | $239.55M | $148.09M | $160.48M | $160.48M |
| Capital Stock | $6,000.00 | $6,000.00 | $5,000.00 | $5,000.00 | $5,000.00 |
| -Common Stock | $6,000.00 | $6,000.00 | $5,000.00 | $5,000.00 | $5,000.00 |
| Additional Paid-In Capital | $560.10M | $556.56M | $451.37M | $449.76M | $449.76M |
| Retained Earnings | -$331.52M | -$316.95M | -$303.45M | -$289.73M | -$289.73M |
| Gains/Losses Not Affecting Retained Earnings | -$528,000.00 | -$67,000.00 | $157,000.00 | $435,000.00 | $435,000.00 |
| Prepaid Assets | – | $3.51M | $3.84M | $4.77M | $4.77M |
| Other Current Liabilities | – | $295,000.00 | $113,000.00 | $59,000.00 | $59,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$12.00M | -$10.55M | -$14.38M | -$54.36M | -$15.64M |
| Net cash flow from continuing operations | -$12.00M | -$10.55M | -$14.38M | -$54.36M | -$15.64M |
| Net Income from Continuing Operations | -$14.57M | -$13.50M | -$13.72M | -$59.85M | -$17.52M |
| Gain/Loss from Continuing Operations | $2,000.00 | -$16,000.00 | $21,000.00 | $18,000.00 | -$5,000.00 |
| Depreciation & Depletion & Amortization | $195,000.00 | $33,000.00 | $38,000.00 | $97,000.00 | $30,000.00 |
| Other Non-Cash Items | $222,000.00 | -$1,000.00 | $58,000.00 | $201,000.00 | $57,000.00 |
| Change in Working Capital | $579,000.00 | $1.84M | -$2.07M | -$601,000.00 | $1.27M |
| -Change in Prepaid Assets | -$648,000.00 | $327,000.00 | $929,000.00 | -$816,000.00 | -$706,000.00 |
| -Change in Payables and Accrued Expense | $2.00M | $1.14M | -$2.94M | $1.94M | $2.01M |
| -Change in Other Current Assets | -$523,000.00 | $304,000.00 | $0.00 | -$1.51M | $0.00 |
| -Change in Other Current Liabilities | -$246,000.00 | $67,000.00 | -$62,000.00 | -$207,000.00 | -$39,000.00 |
| Net cash flow from investing | $6.40M | -$57.26M | -$12.96M | $2.83M | $25.54M |
| Net Cash Flow from Continuing Investing Activities | $6.40M | -$57.26M | -$12.96M | $2.83M | $25.54M |
| Net PPE Purchase and Sale | -$820,000.00 | – | – | -$186,000.00 | $0.00 |
| Net Investment Purchase and Sale | $7.22M | -$57.00M | -$12.96M | $3.02M | $25.54M |
| Financing Cash Flow | $1.22M | $103.70M | $5,000.00 | -$21,000.00 | -$21,000.00 |
| Net Cash Flow from Continuing Financing Activities | $1.22M | $103.70M | $5,000.00 | -$21,000.00 | -$21,000.00 |
| Net Common Stock Issuance | $0.00 | – | – | $0.00 | $0.00 |
| Proceeds from Stock Option Exercised | $1.50M | $335,000.00 | $5,000.00 | $65,000.00 | $65,000.00 |
| Ending Cash Balance | $39.87M | $44.25M | $8.36M | $35.69M | $35.69M |
| Net Change in Cash | -$4.38M | $35.89M | -$27.33M | -$51.54M | $9.88M |
| Beginning Cash Balance | $44.25M | $8.36M | $35.69M | $87.23M | $25.80M |
| Effect of Exchange Rate Changes | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | -$12.82M | -$10.81M | -$14.38M | -$54.54M | -$15.64M |
| Net Other Financing Charges | – | – | – | -$86,000.00 | – |
No comments yet — be the first to weigh in on CLYM.
Sign in to join the discussion.